Arsenic trioxide causes redistribution of cell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells

Cancer Investigation

Volumn 22, Issue 3, 2004, Pages 389-400

  Li, Xinquan ^a   Ding, Xianzhong ^a   Adrian, Thomas E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Arsenic trioxide; Breast; Cancer; Colon; Pancreas

Indexed keywords

ARSENIC TRIOXIDE; CASPASE; CASPASE 3; CASPASE 7; CASPASE 9; DEOXYURIDINE TRIPHOSPHATE DERIVATIVE; DNA; DNA FRAGMENT; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROPIDIUM IODIDE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; THYMIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NICK END LABELING; PANCREAS CANCER; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CASPASE 3; CASPASES; CCAAT-ENHANCER-BINDING PROTEINS; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; COLONIC NEOPLASMS; DNA FRAGMENTATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENES, BCL-2; GROWTH INHIBITORS; HUMANS; IN SITU NICK-END LABELING; NEOPLASM PROTEINS; NUCLEAR PROTEINS; OXIDES; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSCRIPTION FACTOR CHOP; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 4744359324     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-200029068     Document Type: Article

References (38)

1. Antman, K.H. Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 2001, 6 (Suppl 2), 1-2.
2. Rust, D.M.; Soignet, S.L. Risk/benefit profile of arsenic trioxide. Oncologist 2001, 6 (Suppl 2), 29-32.
3. Waxman, S.; Anderson, K.C. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001, 6 (Suppl 2), 3-10.
4. Forlner, C.E.; Scott, T.F.M. Arsenic as a therapeutic agent in chronic myelogenous leukemia. JAMA 1931, 97 (1), 3-5.
5. Sun, H.D.; Ma, L.; Hu, X.C.; Zhang, T.D. Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin. J. Integr. Chin. West Med. 1992, 12 (4), 170-172.
6. Shen, Z.X.; Chen, G.Q.; Ni, J.H.; Li, X.S.; Xiong, S.M.; Qiu, Q.Y.; Zhu, J.; Tang, W.; Sun, G.L.; Yang, K.Q.; Chen, Y.; Zhou, L.; Fang, Z.W.; Wang, Y.T.; Ma, J.; Zhang, P.; Zhang, T.D.; Chen, S.J.; Chen, Z.; Wang, Z.Y. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997, 89 (9), 3345-3360.
7. Chen, Z.; Chen, G.Q.; Shen, Z.X.; Chen, S.J.; Wang, Z.Y. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies. Semin. Hematol. 2001, 38 (1), 26-36.
8. Soignet, S.L.; Maslak, P.; Wang, Z.G.; Jhanwar, S.; Calleja, E.; Dardashti, L.J.; Corso, D.; DeBlasio, A.; Gabrilove, J.; Scheinberg, D.A.; Pandolfi, P.P.; Warrell, R.P., Jr. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 1998, 339 (19), 1341-1348.
9. Bachleitner-Hofmann, T.; Gisslinger, B.; Grumbeck, E.; Gisslinger, H. Arsenic trioxide and ascorbic acid: synergy with potential implication for the treatment of acute myeloid leukaemia. Br. J. Haematol. 2001, 112 (3), 783-786.
10. Kwong, Y.L.; Au, W.Y.; Chim, C.S.; Pang, A.; Suen, C.; Liang, R. Arsenic trioxide-and idarubicin-induce remissions in relapsed acute promyelocytic leukemia: clinicopathological and molecular features of a pilot study. Am. J. Hematol. 2001, 66 (4), 274-279.
11. 3 exert dose-dependent dual effect on APL cells. Blood 1997, 89 (9), 3345-3353.
12. Shao, W.; Fanelli, M.; Ferrara, F.F.; Riccioni, R.; Rosenauer, A.; Davison, K.; Lamph, W.W.; Waxman, S.; Pelicci, P.G.; Lo Coco, F.; Avvisati, G.; Testa, U.; Peschle, C.; Gambacorti-Passerini, C.; Nervi, C.; Miller, W.H., Jr. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells. J. Natl. Cancer Inst. 1998, 90 (2), 124-133.
13. Wang, Z.G.; Rivi, R.; Delva, L.; Konig, A.; Scheinberg, D.A.; Gambacorti-Passerini, C.; Gabrilove, J.L.; Warrell, R.P., Jr.; Pandolfi, P.P. Arsenic trioxide and melarsorol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RAR alpha independent manner. Blood 1998, 92 (5), 1497-1504.
14. Roboz, G.J.; Dias, S.; Lam, G.; Lane, W.J.; Soignent, S.L.; Warrell, R.P., Jr.; Rafii, S. Arsenic trioxide induces dose-and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000, 96 (4), 1525-1530.
15. Gallagher, R.E. Co-biomodulation with arsenic trioxide in multiple myeloma. Leuk. Res. 2001, 25 (3), 237-239.
16. 3) on myeloma cells. Leuk. Res. 2001, 25 (3), 227-235.
17. Munshi, N.C. Arsenic trioxide: an emerging therapy for multiple myeloma. Oncologist 2001, 6 (Suppl 2), 17-21.
18. Shen, Z.Y.; Tan, L.J.; Cai, W.J.; Hong, C.; Zheng, M.H. Arsenic trioxide induces apoptosis of oesophageal carcinoma in vitro. Int. J. Mol. Med. 1996, 4 (1), 33-37.
19. Shen, Z.Y.; Shen, J.; Cai, W.J.; Hong, C.; Zheng, M.H. The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells. Int. J. Mol. Med. 2000, 5 (2), 155-158.
20. Seol, J.G.; Park, W.H.; Kim, E.S.; Jung, C.W.; Hynn, J.M.; Kim, B.K.; Lee, Y.Y. Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1. Biochem. Biophys. Res. Commun. 1996, 265 (2), 400-404.
21. Zhang, T.C.; Cao, E.H.; Li, J.F.; Ma, W.; Qin, J.F. Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur. J. Cancer 1996, 35 (8), 1258-1263.
22. Zheng, J.; Deng, Y.P.; Lin, C.; Fu, M.; Xiao, P.G.; Wu, M. Arsenic trioxide induces apoptosis of HPV 16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression. Int. J. Cancer 1999, 82 (2), 286-292.
23. Jiang, X.H.; Wong, B.C.Y.; Yuen, S.T.; Jiang, S.H.; Cho, C.H.; Lai, K.C.; Lin, M.C.M.; Kung, H.F.; Lam, S.K. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int. J. Cancer 2001, 91 (2), 173-179.
24. Uslu, R.; Sanli, U.A.; Sezgin, C.; Karabulut, B.; Terziohlu, E.; Omay, S.B.; Goker, E. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin. Cancer Res. 2000, 6 (12), 4957-4964.
25. Akao, Y.; Nakagama, Y.; Akiyama, K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase-3 in vitro. FEBS Lett. 1999, 455 (1-2), 59-62.
26. Wang, Z.H.; Yu, D.; Li, H.K.; Chow, V.W.; Ng, C.C.; Chan, H.B.; Cheng, S.B.; Chew, B.C. Alteration of nuclear matrix protein composition of neuroblastoma cells after arsenic trioxide treatment. Anticancer Res. 2001, 21 (1A), 493-498.
27. Griffin, R.J.; Lee, S.H.; Rood, K.L.; Stewart, M.J.; Lyons, J.C.; Lew, Y.S.; Park, H.; Song, C.W. Use of arsenic trioxide as an antivascular and thermo-sensitizing agent in solid tumors. Neoplasia 2000, 2 (6), 555-560.
28. Aposhian, V.; Zakharyan, R.A.; Wildfang, E.K.; Radabaugh, T.R.; Badghisi, H.; Aposhian, M.M. Biodiversity of inorganic arsenic methyltransferases. Toxicol. Sci. 1999, 49 (1), 7-8.
29. Eguchi, N.; Kuroda, K.; Endo, G. Metabolites of arsenic induced tetraploids and mitotic arrest in cultured cells. Arch. Environ. Contam. Toxicol. 1997, 32 (2), 141-145.
30. Gurr, J.R.; Liu, F.; Lynn, S.; Jan, K.Y. Calcium-dependent nitric oxide production is involved in arsenite-induced micronuclei. Mutat. Res. 1998, 416 (3), 137-148.
31. Thornberry, N.A.; Lazebnik, Y. Caspase: enemies within. Science 1998, 281 (5381), 1312-1316.
32. Mancini, M.; Nicholson, D.W.; Roy, S.; Thornberry, N.A.; Peterson, E.P.; Casciola-Rosen, L.A.; Rosen, A. The caspase-3 precursor has a cytosolic and mitochondrial distribution: implications for apoptotic signaling. J. Cell Biol. 1998, 140 (6), 1485-1495.
33. Kothakota, S.; Azuma, T.; Reinhard, C.; Klipel, A.; Tang, J.; Chu, K.; McGarry, T.J.; Kirschner, M.W.; Koths, K.; Kwiatkowski, D.J.; Williams, L.T. Caspase-3 generated fragment of gelsolin: effector of morphological change in apoptosis. Science 1997, 278 (5336), 294-298.
34. Waga, S.; Hannon, G.J.; Beach, D.; Stillman, B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994, 369 (6481), 574-578.
35. Takahashi, S.; Saito, S.; Ohtani, N.; Sakai, T. Involvement of the Oct-1 regulator element of the gadd45 promoter in the p53 independent response to ultraviolet irradiation. Cancer Res. 2001, 67 (3), 1187-1195.
36. Patton, G.W.; Paciga, J.E.; Shelley, S.A. NR8383 alveolar macrophage toxic growth arrest by hydrogen peroxide is associated with induction of growth-arrest and DNA damage-inducible genes GADD45 and GADD153. Toxicol. Appl. Pharmacol. 1997, 147 (1), 126-134.
37. Ou, Y.C.; Thompson, S.A.; Kirchner, S.C.; Kavanagh, T.J.; Faustman, E.M. Induction of growth arrest and DNA damage-inducible genes gagg45 and gadd153 in primary rodent embryonic cells following exposure to methymercury. Toxicol. Appl. Pharmacol. 1997, 147 (1), 31-38.
38. Carrier, F.; Zhan, Q.; Alamo, I.; Hanaoka, F.; Fornace, A.J. Evidence for distinct kinase-mediated pathways in GADD gene responses. Biochem. Pharmacol. 1998, 55 (6), 853-861.